This biotech stock, the first stock I recommended two years ago when I became editor of this newsletter, announced that its primary new antibiotic, eravacycline, had not proved to be any better than the generic drug levofloxacin in a Phase 3 trial for complex urinary tract infections.
The post How to Play This Biotech Stock After Yesterday’s Announcement That a Phase 3 Trial Failed appeared first on Agora Financial.
